Treatment of hospital-acquired bacterial pneumonia Mersadon innovative antibiotic approved by FDA

HABP/VABP is a type of pneumonia that occurs mostly in hospitalized patients and can cause symptoms such as fever, chills, cough, chest pain and increased oxygen demandMany of the bacteria that cause HABP and VABP to become resistant to existing antibiotics due to the overuse of antibioticsPatients therefore need new antibiotics to control bacterial infectionsRecarbrio is a compound of amine pernan, sistadin and relebactamRelebactam is a dinitrogen heterocyclic beta-lactam enzyme inhibitor with broad-spectrum anti-beta endamide enzyme activityAlthough beta-lactamase inhibitors themselves are not antibiotic active, they can enhance the activity of beta-lactam antibioticsRecarbrio has been granted FDA-awarded Qualified Infectious Disease Products (QIDP), Fast Track and Priority Reviewthe safety and efficacy of Recarbrio's treatment of HABP/VABP was tested in a randomized controlled clinical trial of habP/VABP hospitalized patients with 535 cases of Gram-negative bacterial infectionIn this trial, 266 patients were treated with Recarbrio and 269 patients were treated with parrasilin and thaphambatamanWithin 28 days of treatment, 16% of patients treated with Recarbrio died, and the mortality rate was 21% for those treated with parrasilin and taprefen", as a public health agency, the FDA addresses the threat of antibiotic-resistant infections by promoting the development of new and effective treatments"These efforts provide more options for fighting serious bacterial infections and provide patients with safe and effective new treatments as soon as possible," said DrSumathi Nambiar, director of the Anti-Infective Drugs Division at the FDA Drug Assessment and Research Center's Office of Infectious Diseases"